Accelerate Diagnostics — 39th Annual J.P. Morgan Healthcare Conference 2021
27 slides from Accelerate Diagnostics's conference presentation, Jan 13, 2021

Slide 1: 39th Annual J.P. Morgan Healthcare Conference
Jack Phillips President & CEO Accelerate Diagnostics, Inc January 2021 39 TH ANNUAL J.P. Morgan Healthcare Conference

Slide 2: Cautionary Note On Forward-Looking Statements
2 Cautionary Note On Forward - Looking Statements © Copyright 2021 Accelerate Diagnostics, Inc. All Rights Reserved. The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and diamond shaped logos and marks are registered trademarks of Accelerate Diagnostics, Inc. All other t

Slide 3: Purpose and Mission
PURPOSE We deliver lifesaving answers for patients with serious infections MISSION Expand our market leadership in Rapid ID/AST by delivering innovation with clear clinical and financial value for health systems and patients 3

Slide 4: Sepsis is the most significant cost and source of mortality in U.S. hospitals
270,000 deaths in the U.S. annually 2 Sepsis is the most significant cost and source of mortality in U.S. hospitals 1. U.S. Department of Health and Human Services study: Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis, 2012 - 2018 (Ma rch 2020) 2. Centers for Disease Control and Preve

Slide 5: The high cost of sepsis is worsening due in part to rising antimicrobial resistance
The high cost of sepsis is worsening due in part to rising antimicrobial resistance 1 in 3 1. NIH study by Burnham et al. https:// dx.doi.org /10.1017/ice.2018.304 2. U.S. Department of Health and Human Services study: Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis, 2012 - 2018 (Ma rc

Slide 6: COVID is exacerbating the problem
COVID - 19 is exacerbating the problem 72% of COVID - 19 patients received antibiotics when not clinically indicated 1 Langford BJ, So M, Raybardhan S, et al. Bacterial co - infection and secondary infection in patients with COVID - 19: a living rapid review and meta - analysis. Clin Microbiol Infec

Slide 7: Most of the costs of sepsis are avoidable
Most of the costs of sepsis are avoidable 80% of sepsis deaths could be prevented with rapid diagnosis and treatment 7.6% decrease in chance of survival per hour of delay of effective therapy Kumar A, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical

Slide 8: Conventional methods are too slow to affect the change needed
Conventional methods are too slow to affect the change needed for hospitals and patients Based on studies by Accelerate Pheno ® system customers. 8

Slide 9: Our solution is the Accelerate Pheno system
Our solution is the Accelerate Pheno ® system Fast, actionable results faster time to optimal therapy Based on studies by Accelerate Pheno ® system customers. 9

Slide 10: The Accelerate Pheno delivers proven system-wide clinical and economic benefits
Cost Savings $1,000 – 3,100 per patient Shorter Length of Stay 2 days Mortality Reduction 8 % Shorter Time to Optimal Therapy 1.1 – 2.2 days Reduced ABX Usage 2 days on therapy Based on studies by Accelerate Pheno ® system customers. The Accelerate Pheno delivers proven system - wide clinical and ec

Slide 11: First mover advantage in highest-acuity segment of substantial IVD market
ID/AST restated market value 1 $3.7B ID/AST tests per annum 2 All Other Micro Samples 2 Blood Resp. >100M tests North America EMEA APAC 3 Total Blood: 2.3 1.9 3.3 7.5 Respiratory: 0.9 0.9 0.7 2.5 All Other Micro Samples : 2 38.5 31.8 54.9 125.3 Total: 41.8 34.6 58.9 135.3 (in MM) 1. Approximate figu

Slide 12: Continuing to grow number of live customers in our principal U.S. market
7 54 164 268 Dec-17 Dec-18 Dec-19 Dec-20 1. Contracted Pheno placements by geography: North America: 419, EMEA: 165; Preliminary unaudited 2. Preliminary unaudited 268 Live Phenos , with Backlog of >125 +63% Year - over - year growth in revenue - generating installed base 2 12 Continuing to grow num

Slide 13: Delivered top-line growth and strengthened balance sheet exiting 2020
1. Preliminary unaudited financial results 2. “Includes $32M raised through a recent equity purchase by certain insiders, which is subject to customary closing conditions Revenue: Gross Margin: Net Cash Burn: Cash Balance: +54% U.S. revenue growth over prior year $11.2M ~ 40% $41M ~ $100M 2 13 Deliv

Slide 14: Three-year plan to grow Pheno market share and expand available market
Optimize the selling, implementation, and robustness of Pheno offering Expand the available market through new geographies, partnerships, and Pheno 2.0 3 - year plan to significantly grow Pheno market share and expand available market with Pheno 2.0 Accelerate the Pheno opportunity through PhenoAST

Slide 15: Optimize the selling, implementation, and robustness of Pheno offering
Optimize the selling, implementation, and robustness of Pheno offering 15

Slide 16: Optimizing the sales process
Optimizing the sales process Leverage growing & dedicated customer base for aggressive share capture: Referral & regional strategy expansions Improving access to new opportunities Increasing focus on secondary infections, bed utilization, and antimicrobial resistance due to COVID 44% conversion of c

Slide 17: Optimizing implementation process and product robustness
164 197 201 223 268 Dec-19 Mar-20 Jun-20 Sep-20 Dec-20 17 Implementation Process Process overhaul showing strong results 100% forecast accuracy for Q4 Trending toward target of 6 - 9mo average time to go - live Product Robustness Continued focused on customer experience with Pheno Continued ID & AST

Slide 18: Accelerate the Pheno opportunity through PhenoAST and PhenoPrep product extensions
Accelerate The Pheno opportunity through Accelerate PhenoAST ™ and Accelerate PhenoPrep® product extensions 18

Slide 19: Accelerating market penetration through Pheno product extensions
Accelerating market penetration through Pheno product extensions MARKET SHARE TIME PhenoTest BC Kit Extensions PhenoAST (AST - only test on Pheno) PhenoPrep (automated MALDI workflow) 19

Slide 20: Accelerating market penetration through launches of PhenoAST and PhenoPrep
Accelerating market penetration through launches of PhenoAST and PhenoPrep product extensions PhenoPrep Existing MALDI PhenoAST Conventional Customer (Slow ID&AST) Fast ID Customer (Rapid ID & Slow AST) MALDI ID Customer (Slow or Rapid MALDI ID & Slow AST) ID/AST Workflow Today Rapid Pheno Workflows

Slide 21: Expand the available market through new geographies, partnerships, and Pheno 2.0
Expand the available market through new geographies, partnerships, and Pheno 2.0 21

Slide 22: Continuing Geographic Expansion
Continuing Geographic Expansion China clinical trials continue • Continue Type Testing and clinical trial preparations • Secured first clinical customer in Hong Kong • Continue to build regional KOL network 22 EMEA restructuring complete • Focused approach in Southern Europe and the Middle East • Im

Slide 23: Synergistic Partnerships
Synergistic Partnerships DIAGNOSTIC STEWARDSHIP ANTIBIOTIC STEWARDSHIP Clinical Patient Evaluation Testing for Infection Source & Type Adjust & Optimize Therapy Early Detection Detection & Culture ID/AST Host Response Ascend MALDI Partnership Other synergistic partnerships across the sepsis manageme

Slide 24: Pheno 2.0, a step-function innovation in rapid AST
Pheno 2.0, a step - function innovation in rapid AST 24 Current prototype puts Pheno 2.0 on track to be: = $ $ Equivalent accuracy & MICs across broad drug panel 1/10 instrument size & cost Accurate Higher Throughput Lower Cost 1/10 consumable cost < Multi - sample Capable Pheno Pheno 2.0 Enabling i

Slide 25: 2021 Expectations
Optimize Significantly more new customers contracted Go - Live cycle approaching 9 months Product optimizations delivered Expand Achieve Pheno 2.0 milestone Deliver revenue - generating partnership Complete first phase of China registration process COVID - 19 continues to impact hospital access, the

Slide 26: 3-Year Market Expansion Expectations
3 - Year Market Expansion Expectations Market share growth and innovation significantly expand available market 1 $1B Pheno + Product Extensions Addressable Market >$3B Market expansion with Pheno 2.0 launch & entry into Chinese market ▪ Long - term gross margin target of ~70% ▪ Strategic importance

Slide 27: Summary
Summary WHO WE ARE A diagnostics company based in Arizona, founded in 2012, with the purpose of delivering lifesaving answers for patients with serious infections. THE PROBLEM Due to the overuse of antibiotics, the human and hospital costs of treating conditions like sepsis are increasing. Each year
Source: SEC EDGAR · 8-K filed Jan 13, 2021


